TACE


Also found in: Dictionary, Thesaurus, Acronyms, Wikipedia.

TACE

 [tās]
trademark for preparations of chlorotrianisene, a synthetic estrogen used for palliative treatment of prostate cancer and for replacement therapy.

ADAM1bha17

An ADAMs family protein encoded by ADAM17 on chromosome 2p25, which acts as a tumour necrosis factor-alpha converting enzyme (TACE). It binds mitotic arrest-deficient 2 protein, and plays a key role in activating Notch signalling, resulting in the proteolytic release of cell-surface proteins, including p75 TNF-receptor, IL-1 receptor type II, p55 TNF-receptor, TGF-alpha, L-selectin, growth hormone receptor, MUC1 and amyloid precursor protein (APP).

transcatheter arterial chemoembolization

(trans″kath′ĕt-ĕr),

TACE

A technique for destroying tumors in which a tube is guided into the arterial blood supply of the tumor and drugs, fragments of muscle, or synthetic spheres are introduced to obstruct the artery. It is used to treat liver cancers that cannot be removed surgically.
References in periodicals archive ?
BCLC: Barcelona Clinic Liver Cancer; RFA: radiofrequency ablation therapy; TACE: transarterial chemoembolization; TAE: transarterial embolization.
The immediate CT scan revealed that lipiodol was concentrated in the tumor and the effect of TACE was significant.
All patients underwent quadruple-phase MDCT (unenhanced, arterial, portal venous, delayed phases) before and after TACE. MDCT images were obtained using a 64-row helical CT scanner) (SOMATOM Definition, Siemens Medical Solutions) with the following scanning protocol: tube voltage, 80-100 kVp; beam collimation, 14x1.2 mm; pitch, 0.6; tube current product value, 180 mAs; rotation time, 0.5 s.
TACE = transcatheter arterial chemoembolization, RFA = radiofrequency ablation, Y-90 = yttrium-90 radioembolization, and SBRT = stereotactic body radiation therapy.
Five weeks after undergoing TACE, he was readmitted with hematochezia and hemorrhagic shock.
Ermert, "In situ localization of TNF[alpha]/[beta], TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue," Cytokine, vol.
Variables AFP [greater AFP < 20 ng/ml P than or equal to] 20 ng/ml First-line chemotherapy regimens Platinum-based doublet 46 (62.2%) 156 (63.7%) regimen Taxane-based doublet 13 (17.6%) 44 (18.0%) regimen Triplet regimen 9 (12.2%) 17 (6.9%) 0.325 Single-drug regimen 6 (8.1%) 19 (7.8%) Others 0 (0.0%) 9 (3.7%) Response of first-line chemotherapy PR 28 (41.2%) 106 (56.1%) 0.024 SD + PD 40 (58.8%) 83 (43.9%) Subsequent therapies after the first-line chemo Second-line chemotherapy Yes 24 (40.0%) 97 (53.0%) 0.055 No 36 (60.0%) 86 (47.0%) Surgery treatment Yes 1 (1.4%) 8 (3.3%) 0.344 No 73 (98.6%) 237 (96.7%) Local treatment of LM (a) Yes 23 (31.1%) 60 (24.5%) 0.163 No 51 (68.9%) 185 (75.5%) (a) Including TACE, ablation, radiotherapy, and liver resection.
AFP: Alpha-fetoprotein HCC: Hepatocellular carcinoma LT: Liver transplantation TACE: Transarterial chemoembolization.
A 57-year-old male with a past medical history of cirrhosis and HCC secondary to chronic alcohol abuse and hepatitis C infection was undergoing serial transarterial chemoembolization (TACE) procedures.
Most newly diagnosed HCC cases are at an intermediate advanced stage, and the therapeutic options are limited to palliative approaches using TACE or chemotherapeutic agents [5, 40].